Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.

Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM.

Eur Urol. 2020 Feb;77(2):201-208. doi: 10.1016/j.eururo.2019.10.008. Epub 2019 Nov 10.

PMID:
31718822
2.

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.

Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU.

Eur Urol. 2020 Jan;77(1):3-10. doi: 10.1016/j.eururo.2019.03.022. Epub 2019 Apr 13.

PMID:
30992160
3.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.

Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR.

JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732.

4.

Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

Coen JJ, Zietman AL, Thakral H, Shipley WU.

J Clin Oncol. 2002 Aug 1;20(15):3199-205.

PMID:
12149291
5.

Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.

Hayman J, Phillips R, Chen D, Perin J, Narang AK, Trieu J, Radwan N, Greco S, Deville C Jr, McNutt T, Song DY, DeWeese TL, Tran PT.

Prostate. 2018 Jun;78(8):623-630. doi: 10.1002/pros.23507. Epub 2018 Mar 9.

PMID:
29520847
6.

Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.

Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL.

Eur Urol. 2014 Apr;65(4):693-700. doi: 10.1016/j.eururo.2013.05.023. Epub 2013 May 21.

7.

First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.

Kang JJ, Reiter RE, Steinberg ML, King CR.

Eur Urol Oncol. 2018 Oct;1(5):378-385. doi: 10.1016/j.euo.2018.07.008. Epub 2018 Aug 22.

PMID:
31158076
8.

Intermediate Endpoints After Postprostatectomy Radiotherapy: 5-Year Distant Metastasis to Predict Overall Survival.

Jackson WC, Suresh K, Tumati V, Allen SG, Dess RT, Salami SS, George A, Kaffenberger SD, Miller DC, Hearn JWD, Jolly S, Mehra R, Hollenbeck BK, Palapattu GS, Schipper M, Feng FY, Morgan TM, Desai NB, Spratt DE.

Eur Urol. 2018 Oct;74(4):413-419. doi: 10.1016/j.eururo.2017.12.023. Epub 2018 Jan 3.

PMID:
29306514
9.

Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix.

Huang EY, Hsu HC, Sun LM, Chanchien CC, Lin H, Chen HC, Tseng CW, Ou YC, Chang HY, Fang FM, Huang YJ, Wang CY, Lu HM, Tsai CC, Ma YY, Fu HC, Wang YM, Wang CJ.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1105-13. doi: 10.1016/j.ijrobp.2010.07.011. Epub 2010 Oct 6.

PMID:
20932670
10.

The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.

Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M.

Eur Urol. 2015 Feb;67(2):342-6. doi: 10.1016/j.eururo.2014.06.015. Epub 2014 Jun 23.

PMID:
24968968
11.

Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL.

Eur Urol. 2019 Jan;75(1):35-41. doi: 10.1016/j.eururo.2018.08.033. Epub 2018 Oct 24.

PMID:
30554605
12.

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.

Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE.

Eur Urol Oncol. 2018 Sep;1(4):276-282. doi: 10.1016/j.euo.2018.04.014. Epub 2018 Sep 28.

PMID:
31100248
13.

A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.

Van Den Eeden SK, Lu R, Zhang N, Quesenberry CP Jr, Shan J, Han JS, Tsiatis AC, Leimpeter AD, Lawrence HJ, Febbo PG, Presti JC.

Eur Urol. 2018 Jan;73(1):129-138. doi: 10.1016/j.eururo.2017.09.013. Epub 2017 Oct 6.

PMID:
28988753
14.

Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.

Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A.

Eur Urol. 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8.

PMID:
29229176
15.

Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.

Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, Lau H, Duclos M, Parliament M, Morton G, Hamstra D, Seider M, Lock MI, Patel M, Gay H, Vigneault E, Winter K, Sandler H.

JAMA Oncol. 2018 Jun 14;4(6):e180039. doi: 10.1001/jamaoncol.2018.0039. Epub 2018 Jun 14.

16.

Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.

Viers BR, Sukov WR, Gettman MT, Rangel LJ, Bergstralh EJ, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ.

Eur Urol. 2014 Dec;66(6):1116-24. doi: 10.1016/j.eururo.2014.07.004. Epub 2014 Jul 19.

PMID:
25052213
17.

Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.

Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K, Bagrodia A, Gahan JC, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB.

BJU Int. 2018 Mar;121(3):365-372. doi: 10.1111/bju.13926. Epub 2017 Jul 5.

18.

Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.

Ying J, Wang CJ, Yan J, Liauw SL, Straka C, Pistenmaa D, Xie XJ, Lotan Y, Roehrborn C, Kim DN.

Am J Clin Oncol. 2017 Dec;40(6):612-620. doi: 10.1097/COC.0000000000000207.

PMID:
26165416
19.

The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.

Zumsteg ZS, Spratt DE, Romesser PB, Pei X, Zhang Z, Polkinghorn W, McBride S, Kollmeier M, Yamada Y, Zelefsky MJ.

Eur Urol. 2015 Jun;67(6):1009-1016. doi: 10.1016/j.eururo.2014.09.028. Epub 2014 Oct 11.

20.

Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7.

Fosså SD, Wiklund F, Klepp O, Angelsen A, Solberg A, Damber JE, Hoyer M, Widmark A; The Scandinavian Prostate Cancer Group-7 Investigators.

Eur Urol. 2016 Oct;70(4):684-691. doi: 10.1016/j.eururo.2016.03.021. Epub 2016 Mar 26.

PMID:
27025586

Supplemental Content

Support Center